UBS Group
ACHL

UBS Group’s Achilles Therapeutics ACHL Stock Holding History

UBS Group’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,700
Closed -$53.5K – 10254
2024
Q2 		$53.5K Buy
+65,700
New +$57.8K ﹤0.01% 6641
2023
Q2 		– Sell
-12,379
Closed -$11.9K – 9834
2023
Q1 		$11.9K Buy
+12,379
New +$13.4K ﹤0.01% 7471
2022
Q4 		– Sell
-2,657
Closed -$6K – 11258
2022
Q3 		$6K Buy
2,657
+458
+21% +$1.3K ﹤0.01% 9089
2022
Q2 		$6K Sell
2,199
-706
-24% -$1.74K ﹤0.01% 8746
2022
Q1 		$8K Sell
2,905
-2,116
-42% -$7.51K ﹤0.01% 8717
2021
Q4 		$26K Buy
+5,021
New +$30.4K ﹤0.01% 7552
2021
Q3 		– Sell
-464
Closed -$5K – 10214
2021
Q2 		$5K Buy
+464
New +$6.29K ﹤0.01% 8583

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group's ACHL Position: Q3 2024 in Review

UBS Group sold out of Achilles Therapeutics (ACHL) in Q3 2024, closing a stake of 65,700 shares — an estimated $53.5K sold.

UBS Group first reported a position in ACHL in Q2 2021 and held it in 7 quarters. The position peaked at $53.5K in Q2 2024. 22 funds tracked by Wall St. Rank hold ACHL as of Q3 2024.

  • UBS Group reported no remaining Achilles Therapeutics position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 65,700 Achilles Therapeutics shares in Q3 2024, an estimated $53.5K.
  • UBS Group first reported a position in Achilles Therapeutics in Q2 2021 and held it in 7 quarters.
  • UBS Group's Achilles Therapeutics position peaked at $53.5K in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.